Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Proposal On Foreign Device Approval Recognition Due February

Little-used government-industry forum resolves UK must step on the gas to secure timely reform

Executive Summary

The Life Sciences Council has agreed to issue proposals on how the UK should recognize approvals granted by other trusted medical device regulatory jurisdictions. The need for speed in all matters relating to the UK’s sovereign medtech regulatory system has been stressed by the UK devices industry.

You may also be interested in...

UK Posts Sovereign Regulatory System Proposals On Three Priority Areas

Patient safety and continuing access to products have steered UK Life Sciences Council advisory group proposals on recognition of overseas device approvals in Great Britain, speeding innovation to market and ensuring medtech regulatory system capacity.

February Announcements On UK’s Medtech Regulatory System Change Awaited

Much preparation work is underway among industry and the authorities as the UK seeks to nail down what kind of medtech regulatory system it wants for the future. Hosting an update session were the ABHI’s Phil Brown and Steve Lee.

EU MDR Implementation The Clear No.1 Among German Industry’s Top Concerns

Germany’s ZVEI electro and digital industry association, representing the electromedical and health care IT industries, is relieved that the EU is belatedly addressing the MDR’s unrealistic implementation timetable. It is also concerned that the expected changes will still not go far enough.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts